NSAIDs-Related Pyloroduodenal Obstruction and Its Endoscopic Management by Noor, Mohd Talha et al.
Hindawi Publishing Corporation
Diagnostic and Therapeutic Endoscopy
Volume 2011, Article ID 967957, 6 pages
doi:10.1155/2011/967957
Clinical Study
NSAIDs-Related Pyloroduodenal Obstructionand
ItsEndoscopic Management
Mohd Talha Noor,Pankaj Dixit,RakeshKochhar, BirinderNagi, Usha Dutta,
KartarSingh,and Kuchhangi SureshPoornachandra
Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India
Correspondence should be addressed to Rakesh Kochhar, dr kochhar@hotmail.com
Received 31 January 2011; Accepted 20 April 2011
Academic Editor: Tony C. K. Tham
Copyright © 2011 Mohd Talha Noor et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Endoscopic balloon dilatation (EBD) has important role in the management of benign gastric outlet obstruction. Although there
are many reports on the role of EBD in the management of corrosive-induced and peptic benign GOO, there is scanty data on its
role in the management of NSAID-induced GOO. We report 10 cases of NSAID-induced pyloroduodenal obstruction and their
endoscopic management. The most commonsite of involvement was duodenum (5/10) followed by both pylorus and duodenum
(4/10) and pylorus (1/10). Most of the strictures were short web-like, and the mean (SD) number of stricture was 2.0 (0.94).
Endoscopicballoon dilatationwas successful in 90% (9/10) cases requiring mean (SD) of2.0 (1.6) sessionsof dilatation to achieve
target diameter of 15mm and mean (SD) of 5.3 (2.7) sessions to maintain it over a treatment period of 4.5 months (IQR 2–15
months). There was no procedure-related complication or mortality.
1.Introduction
Peptic ulcer disease and corrosive ingestion are the leading
causes of benign gastric outlet obstruction [1]. Nonsteroidal
anti-inﬂammatory drugs (NSAIDs) are known to be associ-
ated with various forms of gastrointestinal injuries including
peptic ulcer disease, diaphragm disease of the bowel, and
protein losing enteropathy [2]. NSAIDs are one of the most
commonly prescribed medications, and they are often used
for long period of time. Chronic NSAID consumption is a
rare cause of gastric outlet obstruction [3–5]. There are case
reports of duodenal web-like strictures associated with long-
term NSAID use [6].
Gastric outlet obstruction (GOO) includes obstruction
in the antropyloric area or in the bulbar or postbulbar
duodenal segments [1]. With the advent of EBD, endoscopic
therapy has become the cornerstone of management of
benign gastric outlet obstruction. A number of reports have
reported the safety and eﬃcacy of the procedure [7, 8]. The
initial experience of EBD was under ﬂuoroscopic guidance;
subsequently it has been shown that EBD can be performed
under endoscopic guidance only [9]. We here report our
experience on gastric outlet obstruction caused by NSAIDs.
2.Methods
Between January 2004 and December 2010, all consecu-
tive patients with symptomatic NSAID-induced GOO were
evaluated. Details of NSAID intake were noted in terms
of type, amount, and duration of intake. All patients
underwent upper gastrointestinal endoscopy, barium meal
follow through, and contrast-enhanced computed tomog-
raphy to note the site and length of gastric and duodenal
stricture(s) and to rule out presence of jejunal and ileal
involvement. Patients who satisﬁed the selection criteria
were subjected to endoscopic balloon dilatation by using
through-the-scope (TTS) balloon dilators. Inclusion criteria
were (1) symptomatic GOO with postprandial vomiting
and (2) narrowing of the pyloroantral area or duodenum
on gastroduodenoscopy and barium meal follow through
examination. Patients with (1) >2.5cm narrowing in the
pyloroantral area and (2) inability to give informed consent2 Diagnostic and Therapeutic Endoscopy
were excluded. Informed written consent was obtained from
each patient at each session, and the study was approved by
the institute ethics committee.
Dilatation was carried out by using wire-guided TTS
CRE(controlledradial expansion) balloon(BostonScientiﬁc
Corp, Marlborough, Mass, USA), after premedication with
intravenous midazolam (Fulse d ;R a n b a x y ,M u m b a i ,I n d i a )
and n-hyoscine butyl bromide (Buscopan;Cadila healthcare,
Goa, India). The barium examination ﬁlms of each patient
were kept in view during dilatation. The diameter of the bal-
loon was selected on the basis of the endoscopist’s subjective
assessment of the severity of the stenosis. The balloon was
negotiated across the narrowed segment under endoscopic
vision and was positioned approximately equally on either
side of the narrowing. Inﬂation was done by using a saline-
solution-ﬁlled syringe mounted on a pressure gun (Alliance
inﬂation device; Boston Scientiﬁc Corp, Marlborough, Mass,
USA) as per manufacturer’s instructions. The CRE balloon
was inﬂated to incremental diameters, for 60 seconds at
each diameter. After deﬂation, the area was observed for
signs of bleeding, and an attempt was made to negotiate
the scope through the narrowed segment. In patients with
multiple strictures, the procedure was repeated at each
narrowing. Patients were observed for 4 hours after the
procedure for pain in the abdomen, tachycardia and a drop
in blood pressure, and only clear liquids were allowed for
24 hours. Dilatation was repeated at 2-3-week intervals until
a 15mm diameter balloon could be passed through the
stricture. All patients were given proton pump inhibitors
in daily doses until the end of dilatation. Once dilatation
to 15mm was achieved, patients were followed up every
2 weeks and were questioned about their symptoms, and
endoscopy was performed. During followup endoscopic
dilatation was performed till there was no residue in two
consecutive endoscopies. Successful dilatation was deﬁned
by the achievement of target diameter (15mm), absence of
symptoms, and no residue in two consecutive endoscopies.
After successful dilatation, all patients were followed at
2-month intervals until December 2010. Recurrence was
deﬁned by the reappearance of symptoms and failure to pass
the diagnostic scope in the previously negotiable stricture.
3.StatisticalAnalysis
Parametric quantitative variables were expressed as mean
(SD); nonparametric quantitative variables were expressed
as median with interquartile range (IQR). Categorical vari-
ables were expressed as percentages. Statistical analysis was
performedusingthestatisticalsoftwarepackageSPSSversion
17.0 (SPSS, Chicago, Illinois, USA).
4.Results
Baseline characteristics of the cases are described in Table 1.
Mean (SD) age of the cases was 45.2 (16.9) years; there
were 8 males and 2 females. Median duration of symptoms
was 9 months (IQR 1–120 months). All the patients had
presented with vomiting (100%), one (12.5%) patient had
Figure 1: Barium meal examination showing two small web like
strictures atthejunction ofthe1stand2ndparts ofduodenum with
proximal dilatation (arrow).
historyofabdominalpain,and3(37.5%)patientshadweight
loss. All the patients had history of consuming NSAIDs. The
number of tablets taken per day ranged from 1 to 8; the
dose of each NSAID taken per day was as per the available
strength in the market multiplied by the average number of
tablets consumed per day. The median duration of NSAID
consumption was 8 years (IQR 3–20 years) (Table 1).
The site of involvement of stricture was pylorus in 5
(50%) patients, duodenum in 9 (90%) patients, and in 4
(40%)patients both thesites were involved,only pylorus was
involved in one patient only. The strictures were in the form
of short 2-3mm web-like circumferential narrowing, except
in 2 patients with pyloric stenosis who had longer (∼5mm)
segments of narrowing (Figure 1). The mean (SD) number
of strictures was 2.0 (0.94). Ulceration at the rim of stricture
was noted in 3 (30%) patients. All the patients underwent
endoscopicstricture dilatationusing CREballoon(Figures2,
3). The mean (SD) number of dilatations to achieve target
diameter of 15mm was 2.0 (1.6). The mean (SD) number of
dilatationsrequiredtomaintain was5.3(2.7).Medianweight
gain was 5kgs (IQR 2–14kgs), and the median duration
of treatment was 4.5 months (IQR 2–15 months). These
patients were followed up to a median of 12 months (IQR
2–16 months). There was no recurrence during this period.
There were no complications like bleeding or perforation,
and there was no mortality. Nine (90%) patients were
managed successfully; only one patient (case no. 2) required
surgery because of failure of endoscopic therapy. He had
two web-like strictures in the second and third parts of
duodenum. Though his strictures could be dilated to 15mm
in 3 sessions, yet he presented with persistent symptoms
and his gastric residue did not decrease. He was consuming
nimesulide for 20 years. He underwent surgery in the form
of gastrojejunostomy.
5.Discussion
In this study we have described the role of endoscopic
dilatation in patients of NSAID-induced pyloroduodenalDiagnostic and Therapeutic Endoscopy 3
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(a) (b)
(c)
Figure 2: Upper gastrointestinal endoscopy showing circular stricture at the junction of the 1st and 2nd parts of duodenum (a), controlled
radial expansion balloon in situ (b), and after dilatation the scope was negotiable into the 2nd part of duodenum (c).
strictures leading to GOO. Nine of the 10 patients could be
successfully treated using EBD, with no recurrence. There
were no procedure-related complications. Only one patient
required surgical management.
Malignancy remains the commonest cause of GOO
but benign etiologies like peptic ulcer disease and caustic
ingestion are responsible for signiﬁcant proportion of such
patients [10]. NSAID ingestion is an uncommon cause of
GOO [3, 4]. Mechanism of GOO caused by NSAID abuse
is not entirely clear. Diminished levels of prostaglandin
E2 have been implicated in the pathogenesis of gastric
outﬂow obstruction by causing pyloric edema and scarring
[11]. Increased histamine release leads to increased gastric
secretion, reduction of mucosal absorption, and gastric
motility disturbances [11]. This suggests a possible mecha-
nism whereby NSAIDs might predispose to gastric outﬂow
obstruction.
NSAIDs can cause strictures anywhere in the gastroin-
testinal tract right from the esophagus to the colon [2, 12,
13]. Small bowel strictures caused by NSAIDs are short (2-
3mm) web-like and are often labeled as diaphragms; they
have been mostly reported in jejunum and ileum [2]. The
predilection for duodenum in our patients may be due
to more frequent use of nonenteric-coated preparations in
India.
EBD is now an established treatment modality in the
managementofbenignGOO.Responsetoendoscopicdilata-
tion depends upon the etiology, length, and site of stricture
[4]. Patients with chronic pancreatitis-related duodenal
stricture have been reported to have the worst outcome with
endoscopicdilatation[4].Needformorethantwosessions of
endoscopic dilatation to relieve symptom is also a predictor
forfailure ofendoscopictherapy in patientswith pepticulcer
disease [14].
There is scanty data on the use of EBD in patients with
NSAID-induced gastric outlet obstruction. In a study from
India, outof 3 patientswith NSAID-inducedduodenalwebs,
two could be managed successfully with endoscopic therapyDiagnostic and Therapeutic Endoscopy 5
TE: p
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Figure 3: Upper gastrointestinal endoscopy of another patient showing pyloric stricture with large antral ulcer (a) and another stricture at
the junction of the 1st and 2nd parts of duodenum (b), and strictures were dilated with controlled radial expansion balloon (c).
in the form of radial incision of webs with mixed cutting and
coagulation current using a sphincterotome [6]. Apart from
this there are only case reports of endoscopic management
of NSAID-induced GOO [15]. The present study is the
largest series on successful management of NSAID-induced
pyloroduodenal obstruction using EBD. With the advent of
doubleballoonenteroscopyNSAID-inducedjejunalandileal
strictures have also been reported to respond to endoscopic
dilatation [16].
The target diameter for EBD for duodenal strictures is
notdeﬁned. Whereas esophagealstrictures need to be dilated
to >14mm and dysphagia occurs with diameter <13mm,
pyloric dilatation is targeted at 15mm [8, 17, 18]. The
duodenum has much larger diameter than pyloric canal, and
thereare no guidelineson theoptimal diameter ofdilatation.
We could achieve a diameter of 15mm in mean of 2 sessions
of EBD, but nearly all the patients had persistence of some
narrowing at follow-up endoscopy along with persistent
gastric residue. Keeping in view our experience with EBD
in caustic-induced GOO, we continued with dilatation with
a 15mm balloon till there was no residue in 2 consecutive
endoscopies and there was no symptom. At this stage all
the patients had easily negotiable strictures. There was no
recurrence over a median follow-up period of 12 months,
although it was short in the last 3 patients.
The main advantage of using EBD for NSAID-induced
GOO is avoidance of surgery in 90% of patients. The
drawback is that the patient has to come for repeated dilata-
tion; this requires long-term commitment and compliance,
median treatment period being 4.5 months. On the other
hand surgery remains a one-time procedure, but it has
signiﬁcant morbidity.
To conclude, NSAID-induced pyloroduodenal strictures
are an uncommon cause of GOO and can be managed
successfully in a majority of patients with EBD. Surgery can
be reserved only for failure of EBD.
Abbreviations
NSAIDs: Nonsteroidal anti-inﬂammatory drugs
GOO: Gastric outlet obstruction
EBD: Endoscopic balloon dilatation.
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